Drug-Drug Interaction Study With Aricept® (Donepezil)

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Alzheimer Disease

Treatments: Drug: Donepezil; Drug: BMS-708163

Study type: Interventional

Funder types: Industry

Identifiers

NCT01042314

CN156-008

Details and patient eligibility

About

The purpose of this study is to find out if the plasma concentration of donepezil is changed when BMS-708163 is administered at the same time

Enrollment: 18 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Healthy men and postmenopausal women

Exclusion criteria

• Medical History and Concurrent Diseases
• Gastrointestinal disease
• Gastrointestinal bleeding disorders
• History of peptic ulcer disease
• History of cholecystectomy
• History of seizure disorder
• History of asthma
• History of Chronic Obstructive Pulmonary Disease
• History of cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes
• Inability to tolerate oral medication
• Inability to be venipunctured and/or tolerate venous access

Trial design

18 participants in 1 patient group

Donepezil and BMS-708163

Experimental group

Treatment:

Drug: BMS-708163

Drug: Donepezil